Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

AN2 Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-21Dec-31-20
   S-1/AS-1/A
Revenues  16.25.4
            Revenue growth  201.1% 
Cost of goods sold  21.67.3
Gross profit  -5.4-1.9
            Gross margin  -33.5%-35.7%
Selling, general and administrative   [+]4.71.3
Other operating expenses  11.54.1
EBIT   [+]-21.6-7.3
            EBIT margin  -133.5%-135.7%
Interest income  0.10.0
Other income (expense), net  0.0-6.3
Pre-tax income  -21.5-13.6
Income taxes  0.00.0
            Tax rate  0.0%0.0%
Net income  -21.5-13.6
            Net margin  -133.3%-253.5%
   
Basic EPS   [+]($8.17)($5.30)
Diluted EPS   [+]($8.17)($5.30)
   
Shares outstanding (basic)   [+]2.62.6
Shares outstanding (diluted)   [+]2.62.6
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy